Episode 25009
Why One Drug Isn't Always Enough... Rich Daly, President & CEO, Catalyst Pharmaceuticals
BioTech Nation ... with Dr. Moira Gunn · Moira Gunn
March 5, 202519m 1s
Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
This week on BioTech Nation, Catalyst Pharmaceuticals CEO Rich Daly discusses the complexities of treating epilepsy and rare diseases. From the challenges of polypharmacy—where patients need multiple drugs to manage a single condition—to the hurdles of diagnosing and treating ultra-rare diseases.
Topics
epilepsyrare diseasesmedical treatmentmultiple medicationspolypharmacyCatalyst Pharmaceuticalspatient caredrug accessibilityseizure managementFicompaFirdapseLambert Eaton Myasthenic Syndromeepilepsy treatmentmedication challengespharmaceutical innovationhealthcare accessrare disease treatmentprescription drugspatient supportspecialty pharmacychronic illnesshealthcare solutionsbiotech industrymedical breakthroughsBiotech NationDr. Moira GunnRich Daly